Outcome Measures in Psoriatic Arthritis: Where Next?

Overview

Journal Musculoskeletal Care

Date 2022 Nov 10

PMID 36356107

Authors

Simon Hackett

Laura C Coates

Affiliations

Soon will be listed here.

Abstract

Objective: To provide an overview of commonly used outcome measure in psoriatic arthritis (PsA).

Background: PsA is a heterogenous inflammatory arthritis, associated with psoriasis that affects between 0.1% and 2% of the population and approximately one in three patients with psoriasis. Psoriatic arthritis places a significant burden on patients' overall quality of life and is associated with a range of comorbidities. Although assessment of patients and monitoring of symptoms has greatly improved over the last 2 decades, capturing disease activity in this multisystem disease remains challenging. Previous efforts have traditionally focussed on assessment of individual disease domains, however recent evidence suggests that composite measurements, particularly those incorporating patient reported outcomes may not only help monitor disease activity more accurately, but also help in accurately validating therapy outcomes in PsA patients.

Purpose: This review discusses currently used outcome measurements in PsA and also highlights the importance of emerging measurements such as biomarkers and their possible role in capturing treatment response.

Citing Articles

Psoriatic arthritis in Jordan: a cross-sectional study of disease characteristics, patient-reported outcomes, and disease activity.

Alnaimat F, Alawneh K, AbuHelal A, Hamdan O, Alelaimat A, Al Mashaleh M BMC Rheumatol. 2025; 9(1):16.

PMID: 39962571 PMC: 11831762. DOI: 10.1186/s41927-025-00468-0.

The impact of psoriatic arthritis on quality of life: a systematic review.

James L, Hailey L, Suribhatla R, McGagh D, Amarnani R, Bundy C Ther Adv Musculoskelet Dis. 2024; 16:1759720X241295920.

PMID: 39717741 PMC: 11664531. DOI: 10.1177/1759720X241295920.

Evaluation of CD4 CD25 CD127 Regulatory T-Cells in Different Stages of Psoriatic Arthritis Patients.

Safari R, Shakurnia A, Ghadiri A, Rajaei E, Mowla K, Haidari M Adv Biomed Res. 2024; 13:77.

PMID: 39512405 PMC: 11542692. DOI: 10.4103/abr.abr_359_23.

Impact of Central Sensitization on Clinical and Functional Aspects of Psoriatic Arthritis.

Kaya M, Tecer D, Kilic O, Ozgunen M, Yilmaz S Medicina (Kaunas). 2024; 60(9).

PMID: 39336490 PMC: 11434392. DOI: 10.3390/medicina60091449.

Management of psoriatic arthritis: a consensus opinion by expert rheumatologists.

DAngelo S, Atzeni F, Benucci M, Bianchi G, Cantini F, Caporali R Front Med (Lausanne). 2023; 10:1327931.

PMID: 38098852 PMC: 10720668. DOI: 10.3389/fmed.2023.1327931.

References

Armstrong A, Patil D, Levi E, McGuiness C, Wang X, Wang Y . Real-World Satisfaction with Secukinumab in Clearing the Skin of Patients with Plaque Psoriasis through 24 Months of Follow-Up: Results from US Dermatology Electronic Medical Records. Dermatol Ther (Heidelb). 2021; 11(5):1733-1749. PMC: 8484392. DOI: 10.1007/s13555-021-00599-5. View

Ritchlin C, Helliwell P, Boehncke W, Soriano E, Hsia E, Kollmeier A . Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced. RMD Open. 2021; 7(1). PMC: 7880108. DOI: 10.1136/rmdopen-2020-001457. View

Coates L, Orbai A, Azevedo V, Cappelleri J, Steinberg K, Lippe R . Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire. Health Qual Life Outcomes. 2020; 18(1):173. PMC: 7282161. DOI: 10.1186/s12955-020-01422-z. View

Kasiem F, Pasma A, Luime J, Tchetverikov I, Wervers K, Korswagen L . A Practical Guide for Assessment of Skin Burden in Patients With Psoriatic Arthritis. J Rheumatol. 2022; 49(10):1117-1123. DOI: 10.3899/jrheum.210550. View

Ademowo O, Hernandez B, Collins E, Rooney C, Fearon U, van Kuijk A . Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis. Ann Rheum Dis. 2014; 75(1):234-41. DOI: 10.1136/annrheumdis-2014-205417. View

Talli S, Etcheto A, Fautrel B, Balanescu A, Braun J, Canete J . Patient global assessment in psoriatic arthritis - what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. Joint Bone Spine. 2015; 83(3):335-40. DOI: 10.1016/j.jbspin.2015.06.018. View

da Cruz Ribeiro E Souza E, da Silva Carneiro S, Yazbek M, de Cassia Menin R, Campanholo C, Carneiro J . Validation and clinical interpretability of PsAID - psoriatic arthritis impact of disease. Adv Rheumatol. 2020; 60(1):49. DOI: 10.1186/s42358-020-00149-1. View

Queiro R, Canete J, Montilla C, Abad M, Montoro M, Gomez S . Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. Arthritis Res Ther. 2017; 19(1):72. PMC: 5372277. DOI: 10.1186/s13075-017-1277-1. View

Fernandez-Sueiro J, Willisch A, Pertega-Diaz S, Pinto Tasende J, Fernandez-Lopez J, Villar N . Validity of the bath ankylosing spondylitis disease activity index for the evaluation of disease activity in axial psoriatic arthritis. Arthritis Care Res (Hoboken). 2010; 62(1):78-85. DOI: 10.1002/acr.20017. View

10.

Coates L, Kavanaugh A, Mease P, Soriano E, Acosta-Felquer M, Armstrong A . Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016; 68(5):1060-71. DOI: 10.1002/art.39573. View

11.

Cassell S, Bieber J, Rich P, Tutuncu Z, Lee S, Kalunian K . The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol. 2007; 34(1):123-9. View

12.

Kaeley G, Eder L, Aydin S, Gutierrez M, Bakewell C . Dactylitis: A hallmark of psoriatic arthritis. Semin Arthritis Rheum. 2018; 48(2):263-273. DOI: 10.1016/j.semarthrit.2018.02.002. View

13.

Mease P . Enthesitis in psoriatic arthritis (Part 3): clinical assessment and management. Rheumatology (Oxford). 2020; 59(Suppl 1):i21-i28. PMC: 7065458. DOI: 10.1093/rheumatology/keaa042. View

14.

Duffy C, Watanabe Duffy K, Gladman D, Brubacher B, Buskila D, Langevitz P . The utility of the arthritis impact measurement scales for patients with psoriatic arthritis. J Rheumatol. 1992; 19(11):1727-32. View

15.

Araujo E, Englbrecht M, Hoepken S, Finzel S, Kampylafka E, Kleyer A . Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum. 2018; 48(4):632-637. DOI: 10.1016/j.semarthrit.2018.05.011. View

16.

Alenius G, Eriksson C, Rantapaa Dahlqvist S . Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis?. Clin Exp Rheumatol. 2009; 27(1):120-3. View

17.

Aktan S, Ilknur T, Akin C, Ozkan S . Interobserver reliability of the Nail Psoriasis Severity Index. Clin Exp Dermatol. 2006; 32(2):141-4. DOI: 10.1111/j.1365-2230.2006.02305.x. View

18.

Helliwell P, Waxman R . Modification of the Psoriatic Arthritis Disease Activity Score (PASDAS). Ann Rheum Dis. 2017; 77(3):467-468. DOI: 10.1136/annrheumdis-2016-211010. View

19.

Billing E, McKenna S, Staun M, Lindqvist U . Adaptation of the Psoriatic Arthritis Quality of Life (PsAQoL) instrument for Sweden. Scand J Rheumatol. 2010; 39(3):223-8. DOI: 10.3109/03009740903347975. View

20.

Coates L, Gladman D, Nash P, FitzGerald O, Kavanaugh A, Kvien T . Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. Arthritis Res Ther. 2018; 20(1):272. PMC: 6286532. DOI: 10.1186/s13075-018-1773-y. View